Stay updated on Pembrolizumab in Neoplasms Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Neoplasms Clinical Trial page.

Latest updates to the Pembrolizumab in Neoplasms Clinical Trial page
- ChecktodayChange DetectedRevision: v3.5.4 was added and Revision: v3.5.3 was removed. This reflects a backend release update and does not alter the visible study information.SummaryDifference0.1%

- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe page’s site/application revision indicator was updated from v3.5.2 to v3.5.3, reflecting a maintenance or release update rather than any change to the underlying study details.SummaryDifference0.1%

- Check29 days agoChange DetectedRevision tag updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check58 days agoChange DetectedSite version updated from v3.4.3 to v3.5.0. No visible changes to the study details, eligibility criteria, or other study content.SummaryDifference0.1%

- Check65 days agoChange DetectedRevision: v3.4.3 now shown, replacing the previous v3.4.2.SummaryDifference0.1%

- Check93 days agoChange DetectedMinor metadata updates were made, including a revision tag (v3.4.2) and update dates (2026-02-10, 2026-01-29, 2026-01). The government funding lapse notice was removed.SummaryDifference0.6%

Stay in the know with updates to Pembrolizumab in Neoplasms Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Neoplasms Clinical Trial page.